|Bid||239.12 x 800|
|Ask||336.67 x 800|
|Day's range||300.98 - 308.27|
|52-week range||261.59 - 509.62|
|Beta (5Y monthly)||0.91|
|PE ratio (TTM)||N/A|
|Earnings date||14 Feb 2024 - 19 Feb 2024|
|Forward dividend & yield||N/A (N/A)|
|1y target est||426.40|
Investors need to pay close attention to Bio-Rad Laboratories (BIO) stock based on the movements in the options market lately.
Bio-Rad's (BIO) margin performance is affected by the inflationary trend of elevated raw material costs, increased logistics costs and higher employee-related expenses.
The deterioration in biopharma and early biotech customer spending and a challenging macroeconomic environment in China impact Bio-Rad's (BIO) Q3 performance.